Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor

Cancer Gene Therapy

Volumn 22, Issue 2, 2015, Pages 95-100

  Singh, H ^a   Moyes, J S E ^a   Huls, M H ^a   Cooper, L J N ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; RETROPOSON;

ANALYTIC METHOD; ANTIGEN EXPRESSION; CELL CULTURE; CROSS LINKING; GENE TRANSFER; HUMAN; LYMPHOCYTOPOIESIS; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; REVIEW; SLEEPING BEAUTY SYSTEM; T LYMPHOCYTE; ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; RETROPOSON;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD19; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; RECEPTORS, ANTIGEN, T-CELL; RETROELEMENTS; T-LYMPHOCYTES;

EID: 84924804013     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2014.69     Document Type: Review

References (55)

1. Nayak S, Herzog RW. Progress and prospects: immune responses to viral vectors. Gene Therapy 2010; 17: 295-304.
2. Najjar AM, Moyes JS, Cooper LJN. DNA plasmids for non-viral gene therapy of cancer. In: Brenner MK, Hung M-C (eds) Cancer Gene Therapy by Viral and Non- Viral Vectors. John Wiley & Sons, 2014 pp 39-59.
3. Yin H, Kan asty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet 2014; 15: 541-555.
4. Ehrhardt A, Xu H, Huang Z, Engler JA, Kay MA. A direct comparison of two nonviral gene therapy vectors for somatic integration: in vivo evaluation of the bacteriophage integrase phiC31 and the Sleeping Beauty transposase. Mol Ther 2005; 11: 695-706.
5. Kawakami K. Tol2: a versatile gene transfer vector in vertebrates. Genome Biol 2007; 8: S7.
6. Wu SC, Meir YJ, Coates CJ, Handler AM, Pelczar P, Moisyadi S et al. piggyBac is a flexible and highly active transposon as compared to sleeping beauty, Tol2, and Mos1 in mammalian cells. Proc Natl Acad Sci USA 2006; 103: 15008-15013.
7. Aronovich EL, McIvor RS, Hackett PB. The Sleeping Beauty transposon system: a non-viral vector for gene therapy. Hum Mol Genet 2011; 20: R14-R20.
8. Izsvak Z, Hackett PB, Cooper LJ, Ivics Z. Translating Sleeping Beauty transposition into cellular therapies: victories and challenges. Bioessays 2010; 32: 756-767.
9. Hackett PB, Largaespada DA, Cooper LJ. A transposon and transposase system for human application. Mol Ther 2010; 18: 674-683.
10. Ahmad M, Rees RC, Ali SA. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 2004; 53: 844-854.
11. Johnson LA, Morgan RA, Dudley ME, Morgan RA, Dudley ME, Cassard L et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114: 535-546.
12. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011; 19: 620-626.
13. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29: 917-924.
14. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129.
15. Peng PD, Cohen CJ, Yang S, Hsu C, Jones S, Zhao Y et al. Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. Gene Therapy 2009; 16: 1042-1049.
16. Field AC, Vink C, Gabriel R, Al-Subki R, Schmidt M, Goulden N et al. Comparison of lentiviral and sleeping beauty mediated alphabeta T cell receptor gene transfer. PLoS One 2013; 8: e68201.
17. Manuri PV, Wilson MH, Maiti SN, Mi T, Singh H, Olivares S et al. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther 2010; 21: 427-437.
18. Nakazawa Y, Huye LE, Salsman VS, Leen AM, Ahmed N, Rollins L et al. PiggyBacmediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther 2011; 19: 2133-2143.
19. Saito S, Nakazawa Y, Sueki A, Matsuda K, Tanaka M, Yanagisawa R et al. Antileukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Cytotherapy 2014; 16: 1257-1269.
20. Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res 2008; 68: 2961-2971.
21. Huang X, Guo H, Kang J, Choi S, Zhou TC, Tammana S et al. Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. Mol Ther 2008; 16: 580-589.
22. Huang G, Yu L, Cooper LJ, Hollomon M, Huls H, Kleinerman ES. Genetically modified T cells targeting interleukin-11 receptor alpha-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res 2012; 72: 271-281.
23. Kumaresan PR, Manuri PR, Albert ND, Maiti S, Singh H, Mi T et al. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci USA 2014; 111: 10660-10665.
24. Ivics Z, Hackett PB, Plasterk RH, Izsvak Z. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 1997; 91: 501-510.
25. Ivics Z, Izsvak Z, Minter A, Hackett PB. Identification of functional domains and evolution of Tc1-like transposable elements. Proc Natl Acad Sci USA 1996; 93: 5008-5013.
26. Izsvak Z, Ivics Z. Sleeping beauty transposition: biology and applications for molecular therapy. Mol Ther 2004; 9: 147-156.
27. Hackett PB Jr., Aronovich EL, Hunter D, Urness M, Bell JB, Kass SJ et al. Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies. Curr Gene Ther 2011; 11: 341-349.
28. Hackett PB, Largaespada DA, Switzer KC, Cooper LJ. Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Transl Res 2013; 161: 265-283.
29. Singh H, Huls H, Kebriaei P, Cooper LJ. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev 2014; 257: 181-190.
30. Kebriaei P, Huls H, Jena B, Munsell M, Jackson R, Lee DA et al. Infusing CD19- directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther 2012; 23: 444-450.
31. Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G et al. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS One 2013; 8: e64138.
32. Wang X, Naranjo A, Brown CE, Bautista C, Wong CW, Chang WC et al. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale. J Immunother 2012; 35: 689-701.
33. Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother 2009; 32: 169-180.
34. Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother 2009; 32: 689-702.
35. Riddell SR, Greenberg PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 1990; 128: 189-201.
36. Cooper LJ, Topp MS, Serrano LM, Gonzalez S, Chang WC, Naranjo A et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 2003; 101: 1637-1644.
37. Cooper LJ, Al-Kadhimi Z, Serrano LM, Pfeiffer T, Olivares S, Castro A et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood 2005; 105: 1622-1631.
38. Numbenjapon T, Serrano LM, Chang WC, Forman SJ, Jensen MC, Cooper LJ. Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8(+) T cells. Exp Hematol 2007; 35: 1083-1090.
39. Numbenjapon T, Serrano LM, Singh H, Kowolik CM, Olivares S, Gonzalez N et al. Characterization of an artificial antigen-presenting cell to propagate cytolytic CD19-specific T cells. Leukemia 2006; 20: 1889-1892.
40. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibodybinding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993; 90: 720-724.
41. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009; 21: 215-223.
42. Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X et al. A herceptinbased chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 2009; 183: 5563-5574.
43. Wang J, Jensen M, Lin Y, Sui X, Chen E, Lindgren CG et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther 2007; 18: 712-725.
44. Yvon E, Del Vecchio M, Savoldo B, Hoyos V, Dutour A, Anichini A et al. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res 2009; 15: 5852-5860.
45. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006; 66: 10995-11004.
46. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004; 18: 676-684.
47. Westwood JA, Smyth MJ, Teng MW, Moeller M, Trapani JA, Scott AM et al. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci USA 2005; 102: 19051-19056.
48. Huls MH, Figliola MJ, Dawson MJ, Olivares S, Kebriaei P, Shpall EJ et al. Clinical application of sleeping beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. J Vis Exp 2013; 1: e50070.
49. Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S, Switzer K et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res 2011; 71: 3516-3527.
50. Rushworth D, Jena B, Olivares S, Maiti S, Briggs N, Somanchi S et al. Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity. J Immunother 2014; 37: 204-213.
51. Eibl R, Kaiser S, Lombriser R, Eibl D. Disposable bioreactors: the current stateof- the-art and recommended applications in biotechnology. Appl Microbiol Biotechnol 2010; 86: 41-49.
52. Tran CA, Burton L, Russom D, Wagner JR, Jensen MC, Forman SJ et al. Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: an approach to improving product safety, composition, and production capacity. J Immunother 2007; 30: 644-654.
53. Somerville RP, Devillier L, Parkhurst MR, Rosenberg SA, Dudley ME. Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE(R) bioreactor. J Transl Med 2012; 10: 69.
54. Apel M, Brüning M, Granzin M, Essl M, Stuth J, Blaschke J et al. Integrated clinical scale manufacturing system for cellular products derived by magnetic cell separation, centrifugation and cell culture. Chemie Ingenieur Technik 2013; 85: 103-110.
55. Tewari P, Kumaresan PR, Figliola M, Huls H, Longin K, Ruhnke K et al. Automated production of clinical-grade CMV-specific T cells to implement immunotherapy at the bedside. Biol Blood Marrow Transplant 2014; 20: S136-S137.